Tanvex BioPharma’s First Biosimilar TX01 Receives FDA Approval

Tanvex BioPharma' first biosimilar, TX01, received approval for its Biologics License Application (BLA) from the U.S. Food and Drug Administration (FDA) on June 29, Taiwan time. This milestone allows TX01 to enter the world's largest biosimilar market. It marks the first FDA-approved biosimilar from Taiwan and is also the first FDA-approved filgrastim biosimilar from Asia.